智通财经APP获悉，开拓药业-B(09939)大涨超26%，截至发稿，涨26.32%，报1.44港元，成交额627.72万港元。
消息面上，开拓药业宣布其自主研发、潜在同类首创的KX-826酊治疗脱发的长期安全性III期临床试验已获得顶线数据。数据显示，该项长期安全性临床试验达到主要研究终点，结果具有统计学显著性及临床意义，且安全性和有效性均表现出色。该项长期安全性临床试验是一项多中心、开放标签研究，旨在评估KX-826外用治疗中国脱发患者的长期安全性（治疗时间52周）。
太平洋证券此前研报曾指出，脱发治疗药物及护理产品市场空间广阔且正在稳步增长，该行认为年轻人对外貌形象重视程度更高，消费意愿更强，有着旺盛的防脱需求，未来我国脱发治疗药物渗透率稳步提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.